Trial Profile
Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab (IMMUNONIVO/MelpredictPD1)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- Acronyms IMMUNONIVO
- 23 Dec 2021 Status changed from not yet recruiting to completed.
- 24 Jul 2017 New trial record